FDA approves Novartis' Signifor drug for Cushing’s disease The U.S. Food and Drug Administration today approved Signifor injection for the treatment of Cushing’s disease patients who cannot be helped through surgery. The FDA is requiring three postmarketing studies for Signifor: a clinical trial to assess high blood sugar management; a long-term prospective observational cohort study of patients with Cushing’s disease treated with Signifor; and focused safety monitoring for reports of serious hyperglycemia, acute liver injury, and adrenal insufficiency. Signifor is manufactured by Novartis (NVS). Reference Link
News For NVS From The Last 14 Days
Check below for free stories on NVS the last two weeks.
Novartis treatment for pigmented villonodular synovitis gets orphan designation According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link